Compare FLS & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLS | IBRX |
|---|---|---|
| Founded | 1790 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7B | 7.2B |
| IPO Year | 2006 | 2015 |
| Metric | FLS | IBRX |
|---|---|---|
| Price | $71.06 | $8.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 7 |
| Target Price | ★ $86.00 | $12.57 |
| AVG Volume (30 Days) | 2.0M | ★ 12.0M |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.04% | N/A |
| EPS Growth | 23.36 | ★ 38.71 |
| EPS | ★ 0.64 | N/A |
| Revenue | N/A | ★ $113,288,000.00 |
| Revenue This Year | $6.80 | $88.59 |
| Revenue Next Year | $6.22 | $131.15 |
| P/E Ratio | $108.89 | ★ N/A |
| Revenue Growth | N/A | ★ 668.31 |
| 52 Week Low | $48.71 | $1.95 |
| 52 Week High | $92.41 | $12.43 |
| Indicator | FLS | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 43.69 | 50.67 |
| Support Level | $69.50 | $6.69 |
| Resistance Level | $73.36 | $8.54 |
| Average True Range (ATR) | 2.77 | 0.67 |
| MACD | -0.73 | 0.04 |
| Stochastic Oscillator | 22.96 | 45.31 |
Flowserve Corp is a manufacturer and aftermarket service provider of comprehensive flow control systems. It develops precision-engineered flow control equipment to monitor movement and protect customers' materials and processes. It offers an extensive range of pumps, valves, seals, and services for several industries, including oil and gas, chemical, power generation, and water management. It has three business segments: FPD for custom engineered pumps, pre-configured industrial pumps, pump systems, mechanical seals, auxiliary systems and replacement parts and related services; and FCD for engineered-to-order and configured-to-order isolation values, control valves, valve automation products and related equipment and Eliminations and All Other.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.